PRESS RELEASE
Millenium Biotechnologies Partners with Global Business Coalition on HIV/AIDS to fight HIV/AIDS Epidemic

Consortium Built to Educate and Introduce New Treatments to Global Marketplace

Basking Ridge, NJ, September 10, 2004 – Millennium Biotechnologies, Inc. (OTCBB: MBTG.OB), has partnered with the Global Business Coalition on HIV/AIDS (GBC) to introduce Millennium’s products to the global business community. The GBC is an alliance of over 170 international corporations leading the business fight against the AIDS pandemic.

Millennium Biotechnologies is a pioneer in the research and development of specialized nutritional products, namely Resurgex and Resurgex-plus, which are patented, multi-action, multi-component nutritional formulas designed to address the comprehensive needs of individuals struggling with immuno-compromised conditions such as HIV/AIDS as an adjunct to their medical care. In clinical trials both products have been proven to have significant effect on the health and well being of immuno-compromised patients.

“In partnering with the GBC’s international alliance we are able to educate people living and working with HIV/AIDS about the efficacy of integrating medical nutrition therapy into their treatment regime so they are able to maintain a healthy immune system as well as a healthy lifestyle,” said Jerry Swon, CEO, Millennium Biotechnologies.

“Our partnership with Millennium is a natural one, given that many of our members have implemented comprehensive HIV/AIDS treatment programs and are continually seeking to enhance these programs,” said Patricia Mugambi, director of corporate relations, GBC. “Nutrition is an integral component of care and treatment regimens, and the GBC remains committed to educating our global partners about the most recent nutritional information and products available that can support their ongoing efforts.”

Millennium Biotechnologies joins the ranks of select national and international companies dedicated to promoting the new and innovative opportunities for the business sector to join the growing global movement against this epidemic. For a complete list of GBC member companies please visit file://www.businessfightsaids.org/.

About Millennium Biotechnologies

Millennium Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies, Group Inc. is a pioneer in the research and development and marketing of medical nutritional supplements. Millennium owns the exclusive rights to RESURGEX® and RESURGEX Plusä, multiple action nutritional formulas containing the critically important, orally effective form of (SOD)/Gliadin (Defenzyme™)) and several other essential nutritional components. Millennium products are designed to assist in increasing energy, maintaining lean muscle, reducing oxidative stress and supporting immune function in patients with HIV/AIDS, Hepatitis C, cancer or other immuno-compromised conditions as an adjunct to their medical care. Additional information about Millennium Biotechnologies, Inc., is available at http://www.milbiotech.com/.

Contact:

Katie Bestenlehner / Anne Donohoe
212-896-1269 / 212-896-1261
kbest@kcsa.com / adonohoe@kcsa.com


About The Global Business Coalition on HIV/AIDS
The Global Business Coalition on HIV/AIDS (GBC) is the pre-eminent organization leading the business fight against HIV/AIDS. With offices in New York and Paris, the rapidly-expanding alliance of over 170 international companies is dedicated to combating the AIDS epidemic through the business sector's unique skills and expertise. The mission of the GBC is to harness the power of the global business community to end the HIV/AIDS pandemic. For more information, please visit the GBC website at http://www.businessfightsaids.org/.

Contact:

Barbara Holmes
Director of Communications & Advocacy
The Global Business Coalition on HIV/AIDS
Tel: 212-846-5893
Fax: 212-846-1939


This news release contains forward-looking statements that are based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions on the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.

###